Anti-Inflammatory Neutrophils Reprogram Macrophages Toward a Pro-Healing Phenotype with Increased Efferocytosis Capacity
Overview
Biophysics
Cell Biology
Molecular Biology
Authors
Affiliations
Following myocardial infarction (MI), blood neutrophils quickly and extensively infiltrate the heart, where they are temporally polarized into pro-inflammatory (N1) and anti-inflammatory (N2) subpopulations. Neutrophil transmigration is rapidly followed by the accrual of macrophages (MACs), which are believed to undergo local phenotypic transformations from pro-inflammatory to pro-healing MACs that mediate inflammation resolution. We hypothesized that N2 neutrophils can reprogram MACs toward a healing phenotype with increased efferocytosis capacity. To examine this, human neutrophils isolated from healthy subjects were polarized in N1 and N2 neutrophils, and their secretome was added to human MACs derived from THP monocytes. The impact of neutrophil factors on macrophages was investigated using qPCR, ELISA, Western blot, immunofluorescence, or an efferocytosis assay. The results show that the MACs exposed to N2 neutrophil secretome exhibited (i) increased expression of the anti-inflammatory molecules , TGF-β, and IL-10 and the nuclear factors associated with reparatory macrophages (PPARγ, Nur77, and ); (ii) enhanced expression of efferocytosis receptors (MerTK, , CX3CR1, and ) and of the bridge molecules Mfage8 and Gas6; and (iii) enhanced efferocytosis. In conclusion, factors released by N2 neutrophils induce a pro-healing phenotype of MACs by upregulating anti-inflammatory molecules and efferocytosis receptors and ensuing the efferocytosis capacity. The data suggest that molecular therapy to foster N2 polarization, which boosts macrophages' pro-healing phenotype, could be a promising strategy to speed up inflammation resolution and tissue repair.
Bacterial metabolism in the host and its association with virulence.
Bhagwat A, Haldar T, Kanojiya P, Saroj S Virulence. 2025; 16(1):2459336.
PMID: 39890585 PMC: 11792850. DOI: 10.1080/21505594.2025.2459336.
Li C, Xu W, Li L, Zhou Y, Yao G, Chen G Adv Sci (Weinh). 2024; 11(48):e2408044.
PMID: 39455287 PMC: 11672322. DOI: 10.1002/advs.202408044.
Kang M, Jia H, Feng M, Ren H, Gao J, Liu Y Front Immunol. 2024; 15:1467089.
PMID: 39372400 PMC: 11449765. DOI: 10.3389/fimmu.2024.1467089.
Liu L, Wen Y, Chen L, Li M, Yu J, Tian W Stem Cell Res Ther. 2024; 15(1):270.
PMID: 39183362 PMC: 11346187. DOI: 10.1186/s13287-024-03882-2.
Comprehensive macro and micro views on immune cells in ischemic heart disease.
Zhao Y, Tan M, Yin Y, Zhang J, Song Y, Li H Cell Prolif. 2024; 57(12):e13725.
PMID: 39087342 PMC: 11628753. DOI: 10.1111/cpr.13725.